Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients
Theranostics · 27.01.2025 · 15 (7) · 2672-2679
DOI: 10.7150/thno.108963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 27.01.2025. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radiopharmaceuticals, Radioisotopes. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale: [177Lu]Lutetium prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA) is EMA-approved for certain indications in metastatic castration resistant prostate cancer (mCRPC). However, cancer-control outcomes in specific and trial-underrepresented subgroups are scant.
Methods
We relied on the FRAMCAP database to elaborate progression-free (PFS) and overall (OS) survival in elderly (≥75 yrs), frail (ECOG status ≥1) mCRPC patients or those with cardiovascular disease (CVD) treated with [177Lu]Lu-PSMA.
Results
Of 312 [177Lu]Lu-PSMA mCRPC patients, 76% were ≤75 vs. 24% >75 years. Patients >75 years received [177Lu]Lu-PSMA more frequently within the first three mCRPC lines (85% vs. 62%) and harbored more frequently ECOG status ≥2 (13% vs. 4.3%, both p 75 years was observed (hazard ratios [HR] 0.97 & 0.85, both p≥0.4) with median PFS of 12.7 vs. 11.7 and OS of 15.1 vs. 19.8 months. In ECOG-stratified analyses, no PFS difference was observed, with significantly better OS for ECOG 0 vs. ≥1 (HR 1.69, p < 0.01), but not after further multivariable adjustment. In CVD-stratified analyses, PFS failed to provide significant differences between CVD vs. no CVD (HR: 1.44, p = 0.051). However, in OS analyses, significant worse OS for CVD mCRPC [177Lu]Lu-PSMA patients was observed (HR: 1.93, p < 0.01). After multivariable adjustment, CVD was an independent predictor for worse PFS and OS (both p < 0.01).
Conclusions
Real-world evidence suggests equally effective cancer-control outcomes in elderly and frail mCRPC patients treated with [177Lu]Lu-PSMA. However, patients with CVD are of higher risk for shorter PFS and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
- Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
- Urologische Klinik München Planegg, Planegg, Germany.
- Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Zitieren
APA
Wenzel, M., Siech, C., Garcia, C. C., Humke, C., Groener, D., Kriegmair, M., Graefen, M., Maurer, T., Salomon, G., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients. Theranostics, 15(7), 2672-2679. https://doi.org/10.7150/thno.108963
Vancouver
Wenzel M, Siech C, Garcia CC, Humke C, Groener D, Kriegmair M, et al. Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients. Theranostics. 2025;15(7):2672-2679. doi:10.7150/thno.108963
BibTeX
@article{Wenzel2025,
author = {Wenzel, Mike and Siech, Carolin and Garcia, Cristina Cano and Humke, Clara and Groener, Daniel and Kriegmair, Maximilian and Graefen, Markus and Maurer, Tobias and Salomon, Georg and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
title = {Cancer-control outcomes with [ 177 Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {7},
pages = {2672--2679},
doi = {10.7150/thno.108963}
}
EUVIMED